Skip to content

Sandalwood-mediated OR2AT4 activation regulates paracrine signaling to ameliorate dermal papilla vascular degeneration in androgenetic alopecia

Sandalwood-mediated OR2AT4 activation regulates paracrine signaling to ameliorate dermal papilla vascular degeneration in androgenetic alopecia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120117
Enrollment
Unknown
Registered
2026-03-10
Start date
2024-10-31
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenetic alopecia

Interventions

Sandalore/santalol treatment group:Participants applied a topical scalp oil formulation containing santalol and Sandalore twice daily (morning and evening) to affected scalp areas for 16 weeks.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy males or females aged 18-60 years; 2.Clinical diagnosis of androgenetic alopecia, with males classified as Hamilton-Norwood grade IIIa, III, IIIv, IV, IVa, or V, and females classified as Savin scale D3-D4; 3. No hair dyeing, perming, styling, or other special hair treatments within the past month; 4.Willing to maintain the same hairstyle, hair color, and hair length throughout the study period, and to refrain from using special hair care products or scalp treatments; 5.Able to understand the study procedures, willing to participate voluntarily, and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, or those planning pregnancy in the near future; 2.Patients with severe androgenetic alopecia, alopecia areata, inflammatory scarring alopecia, or other scalp/hair disorders; 3.Individuals with psychiatric or psychological disorders, or those with chronic sleep disturbances or emotional control disorders; 4.Use of anti-hair loss cosmetic products or other products with hair loss prevention or hair growth promotion effects within the past 3 months; 5.Oral or topical use of any medications affecting hair growth within the past 6 months; 6.Previous hair transplantation treatment; 7.Individuals with curly hair; 8.Individuals with hypersensitive constitution; 9.Participation in other clinical trials within the past 2 months; 10.Individuals deemed unsuitable for trial participation based on clinical assessment.

Design outcomes

Primary

MeasureTime frame
Overall hair density;Localized hair density;

Countries

China

Contacts

Public ContactLi Li

West China Hospital of Sichuan University

18838920914@163.com+86 151 3891 3957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026